Xilio Therapeutics prices $50M public offering of warrants; cash runway through Q3 2026

Xilio Therapeutics, Inc.

Net proceeds of ~$46.6M from offering of pre-funded warrants and Series A/B/C warrants, priced at $0.7499 per unit.
Cash runway extended to Q3 2026, assuming no contributions from AbbVie or Gilead partnerships.
Series A warrants exercisable after Dec 1, 2025 or if stock closes above $1.50 for five days; $0.75 exercise price.
Series B and C warrants subject to offset/cancellation if non-dilutive capital ≥$20M received before Dec 1, 2026.
If all Series B and C warrants exercised for cash, additional gross proceeds up to ~$100M.

item 1.01item 7.01item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.